Ona Therapeutics, a Barcelona-based oncology biotech, has raised $86.6m (roughly €80m) in a Series B round to take its first-in-class antibody-drug conjugates (ADCs) into clinical development, according to the Institute for Research in Biomedicine (IRB Barcelona), the research centre from which the company traces its scientific origins. The financing, disclosed on 4 June 2026, is one of the larger biotech rounds tied to Barcelona this year and lands in a city better known for software and robotics than for late-stage drug development.
For a Catalan life-sciences sector that has struggled to keep home-grown discoveries on home soil through the expensive clinical phase, the size of the round matters. ADCs — antibodies engineered to deliver a toxic payload directly to cancer cells while sparing healthy tissue — are among the most contested and best-funded categories in global oncology. Ona says the money will move its lead programmes from the laboratory bench toward first-in-human studies, the stage at which most European biotechs run out of cash or relocate.
What did Ona Therapeutics actually raise?
According to IRB Barcelona, Ona Therapeutics closed an $86.6m Series B. Converted at prevailing rates, that is approximately €80m. The stated purpose is to "advance first-in-class ADCs into clinical development" — in other words, to fund the transition from preclinical research to regulated human trials, the most capital-intensive step a drug developer faces.
Several details that a funding reader would want are not in the source material and should not be guessed. The syndicate of investors and the identity of the lead backer were not disclosed in the announcement available here. The company's post-money valuation was not published. Nor did the source carry Ona's current headcount, the size of any previous seed or Series A round, or the specific tumour types its lead candidates target. Those are named limitations, not omissions to paper over: on the evidence to hand, what is confirmed is the amount, the stage and the intended use of proceeds.
What is on the record is the scientific lineage. Ona Therapeutics is rooted in work carried out at IRB Barcelona, the biomedical research institute on the Barcelona Science Park (Parc Científic de Barcelona), which is why the institute is announcing the round at all. That tie is the reason this is a Barcelona story rather than a generic biotech wire item.
Why does this matter for Barcelona?
Barcelona has spent a decade trying to convert its academic research base — IRB Barcelona, the Barcelona Institute of Science and Technology, and the cluster around the science park — into companies that stay and hire locally. The bottleneck is rarely the science; it is the capital needed to fund clinical trials, which typically runs into tens of millions of euros before a drug generates a cent of revenue. An $86.6m Series B is precisely the cheque size that lets a spin-out reach the clinic without decamping to Boston or Basel.
The round also broadens the picture of what Barcelona funds. The city's most visible recent raises have come from deep tech rather than drug development, such as the €73m Series A landed by Barcelona robotics firm Theker. A Series B of this scale in therapeutics signals that specialist life-sciences investors — the kind who underwrite ADC programmes — are willing to write large cheques into Catalan companies. For local founders, wet-lab talent and contract research organisations, that is a demand signal worth tracking.
How does this compare across Europe?
Against DMK Tribe's other five cities, biotech of this weight is comparatively rare. Paris, Madrid, Milan, Lisbon and Valencia have produced sizeable software, AI and quantum rounds — from Madrid's AI-workforce platforms to Milan's quantum relocations — but ADC drug development sits in a different risk and capital class. Antibody-drug conjugates have attracted some of the largest deals in global pharma over the past two years, with big buyers paying billions for clinical-stage assets. A European ADC company reaching the clinic with fresh capital is the kind of asset those acquirers eventually scout.
That is the strategic read for Barcelona: Ona is not competing with the city's software startups for the same investors or the same talent. It is competing internationally, in a field where a successful clinical readout can trigger a licensing deal or acquisition far larger than the round itself. The flip side is timeline risk — clinical trials take years and most first-in-human candidates fail.
What to watch next
The immediate milestone is Ona filing to begin first-in-human trials and disclosing which tumour indication its lead ADC targets — the moment the programme stops being preclinical. Watch, too, for the company to name its Series B syndicate and any local co-investment, and for a hiring push in clinical operations and regulatory roles around the Barcelona Science Park. Whether this round persuades more Catalan researchers to build companies at home, rather than licensing discoveries abroad, is the longer test — and the one that would actually change the city's life-sciences map.
